BSB-2002 for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive single doses of BSB-2002 in dose escalation cohorts to evaluate safety and determine the maximum tolerated dose
Expansion Cohort
Additional participants are enrolled to further evaluate the safety and efficacy at the maximum tolerated dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BSB-2002
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Once the maximum tolerated dose (MTD) or promising dose is reached additional AML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients will be enrolled in the expansion cohort.
AML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients with an identified will be dosed in dose escalation cohorts
Find a Clinic Near You
Who Is Running the Clinical Trial?
BlueSphere Bio, Inc
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.